MBRX News and Press, Moleculin Biotech Inc. From 10/29/20

Moleculin Biotech (MBRX) inks agreement with the University of Campinas in São Paulo, Brazil to further enable collaboration into its research on the anti-viral capabilities of its drug candidate WP1122, specifically for the coronavirus. Recently the University of Campinas published inde...

Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19 Initial information sharing agreement signed to further research into the anti-viral potential of WP1122 PR Newswire HOUSTON, Oct. 29, 2020 HOUSTON , Oct. 29, 2020 /PRNewswi...

Moleculin to Participate in Panel at ROTH Capital's "COVID-19 Therapeutics in Development" Healthcare Event PR Newswire HOUSTON, Oct. 27, 2020 HOUSTON , Oct. 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a c...

Moleculin Announces Independent Study Validates Annamycin's Ability to Target Lung Localized Tumors Annamycin demonstrated up to 30-fold greater concentration in lungs of Annamycin than the current standard of care drug; enables targeting cancer in its sanctuary site PR News...

Moleculin Biotech (MBRX) announces additional preliminary data from the Phase 1 clinical trial of its immuno-stimulating STAT3 inhibitor, WP1066, in patients with glioblastoma ((GBM)). This supports the progression of the trial to the fourth and final dose escalation cohort.Three patients hav...

Palm Beach, FL – October 13, 2020 – The number of new cases of brain cancer across the world has been growing consistently for years and it is projected to continue on this upward path, which leads to recent reports projecting that the global treatment markets should also see ...

Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial Adult brain tumor trial advances to final dose escalation cohort of WP1066 PR Newswire HOUSTON, Oct. 13, 2020 HOUSTON , Oct. 13, 2020 /PRNewswire/ -- ...

Nano cap Moleculin Biotech (MBRX) perks up 6% premarket on average volume in reaction to its announcement that pipeline candidates WP1096 and WP1097, which have shown activity against SARS-CoV-2, also showed activity against HIV, Zika and Dengue Fever viruses.It has added the two mo...

Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV Also shows activity in Zika and Dengue Fever PR Newswire HOUSTON, Oct. 6, 2020 HOUSTON , Oct. 6, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ...

Moleculin Appoints Elizabeth Cermak to Board of Directors PR Newswire HOUSTON, Oct. 5. 2020 HOUSTON , Oct. 5 . 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a ...